According to Bain & Company’s 2026 Global Healthcare Private Equity Report, 2025 was the largest year on record for pharma services deal value, yet transaction volumes declined 11% CAGR from their 2023 peak. Pharma Services Buyout Activity 2020-2025 Just three
“We’re not trying to be everything for everyone. Our specialized focus has been very exciting for me.” Franco Negron, CEO of Simtra BioPharma Solutions, has transformed a 65-year sterile manufacturing legacy into an independent CDMO since the company’s carve-out from
Johnson & Johnson announced Thursday it has reached an agreement with the Trump administration to reduce prescription drug prices for American patients in exchange for exemptions from pharmaceutical tariffs. The agreement makes J&J the 15th major pharmaceutical company to strike
“Process chemistry alone is no longer the whole story—it needs to be connected with engineering solutions, digital tools, and data utilization” Stefan Randl, Chief Scientific Officer at Siegfried, joined the Swiss-based CDMO in January 2025 after 16 years at Evonik,
“Biotechs need flexibility and have limited budgets, while big pharma looks for long-term partnerships, reliability, scalability, and new technologies.” Luis Berrade, Senior Director of Global Biologics Testing Sales at Charles River Laboratories, has spent his career helping pharmaceutical and biotech
The Pharmaceutical Supply Chain Initiative (PSCI) has released its annual audit findings report, analyzing 2,046 observations from 228 supplier audits conducted in 2024. The analysis, spanning Governance & Management Systems (428 findings), Ethics (26), Human Rights (273), Health & Safety
“Twenty years ago, who knew that ADCs and next-generation bioconjugates were going to be so exciting, so successful?” Campbell Bunce, Chief Scientific Officer at Abzena, reflects on the strategic positioning that has placed his company at the forefront of one
“I got a phone call from the French ambassador, and he said, ‘I need this product which you’re producing in your factory in Warsaw, in France, beginning in one week. We’re running out,’” recalls Markus Sieger, CEO of Polpharma Group,
In pharmaceutical manufacturing, the complexity of outsourcing relationships demands a systematic approach. As external manufacturing networks grow more critical to business success, organizations need a clear framework to guide their supplier management programmes. Each year, State of Flux’s Global SRM
“Our goal is to be recognized for exceptional reliability in our services and manufacturing, while helping our customers bring the most innovative medicines to market.” Dr. Michael Quirmbach, CEO and President of CordenPharma, has overseen remarkable growth at the full-service
